[PDF] Top 20 Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy
Has 10000 "Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy" found on our website. Below are the top 20 most common "Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy".
Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy
... (p,0.05). Central retinal thickness and chor- oidal thickness also significantly decreased at last follow-up ...Conclusion: Half-dose PDT is an effective treatment option for chronic CSR in a ... See full document
5
Efficacy of 1/3 Dose Verteporfin Photodynamic Therapy for Subacute Central Serous Chorioretinopathy
... Central serous chorioretinopathy (CSC) frequently affects young-to-middle-aged men [1] ...the long term, approximately half of the patients experience persistent or recurrent SRF [5] ... See full document
9
Comparing half dose photodynamic therapy with high density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial
... with half the dose of verteporfin and full fluency (energy) of laser treatment, half the fluency level and the full dose of verteporfin, or half the treatment time using ... See full document
17
Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy
... Abstract: Central serous chorioretinopathy (CSCR) is an idiopathic disorder characterized by serous retinal detachments associated with focal leakage on fluorescein angiography and pigment epithelial ... See full document
9
The comparison of multimodal imaging findings of central serous chorioretinopathy patients in regard to the early anatomically treatment response to half-fluence photodynamic therapy: a retrospective case–control study
... Central serous chorioretinopathy was a usually self- limited condition which in general spontaneously resolves within 4–6 months; therefore observation was preferred over treatment in the first ...the ... See full document
8
1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
... the long-term efficacy of PDT is often ...favorable long-term outcomes to foveal atrophy [20], PCV recurrence [20, 21] and CNV development ...the dose of ... See full document
7
Photoreceptor disruption in central serous chorioretinopathy treated by half-dose photodynamic therapy
... standard dose of verteporfin in photodynamic therapy has proven effective for the treatment of longstanding CSC and CSC with leakage at the macula, as it has resulted in subretinal fluid ... See full document
6
Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy
... by half-dose PDT and whether this correlates with treatment ...establish long- term ...short term nature of this study, but they do indicate that automated static perimetry may play a ... See full document
6
Microperimetric evaluation of chronic central serous chorioretinopathy after half-dose photodynamic therapy
... sensitivity measured by Humphrey visual field analyzer and morphological changes in eyes with CSC. They found a significant correlation between retinal sensitivity and height of the serous retinal detachment. It ... See full document
7
Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
... low-fluence photodynamic therapy at baseline (left column) and after therapy (right ...with central serous chorioretinopathy (top ...of therapy (top ... See full document
6
Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy
... This study was performed in accordance with the tenets of the Declaration of Helsinki and was approved by Khon Kaen University Ethics Committee (Khon Kaen, Thailand) for human research (HE551117). Patients who had been ... See full document
5
Newly diagnosed exudative age-related macular degeneration treated with pegaptanib sodium monotherapy in US community-based practices: medical chart review study
... Diabetic Retinopathy Study [ETDRS] letters), and absence of scarring or atrophy within the ...or outcomes were observed among sites using t -test, Wil- coxon test, or Fisher ’ s exact test, as ... See full document
10
Three-year results of a modified photodynamic therapy procedure (Ironing PDT) for age-related macular degeneration patients with large lesions
... patients, photodynamic therapy (PDT) is impor- tant as a second treatment ...with Photodynamic Therapy (TAP) study showed that verteporfin therapy of subfoveal choroidal ... See full document
6
Epimacular brachytherapy for wet AMD: current perspectives
... acids, long-chain [omega-3] prevent development to more advanced stages of the disease), and 10) obesity (high correlation of the disease with high body mass ... See full document
10
Comparing imaging capabilities of spectral domain and swept source optical coherence tomography angiography in healthy subjects and central serous retinopathy
... Central serous retinopathy (CSR), characterized by serous retinal detachment in the macular area, is an eye disease commonly found in young to middle-aged adults [1, ... See full document
9
Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup
... Photodynamic therapy with verteporfin has been the treatment of choice, especially in PVC [12, 14, ...a long followup describes frequent recurrences after PDT [22, ... See full document
11
Changes in visual function and thickness of macula after photodynamic therapy for age-related macular degeneration
... the central visual function in eyes with a subfoveal ...the central vision and result in a scotoma which has only a slight influence on distant vision but has a strong effect on near ... See full document
6
Choroidal neovascularization emerged right from the focal choroidal excavation in eyes with central serous chorioretinopathy post half-dose photodynamic therapy: a case report
... A 46-year-old Chinese female patient presented with 5 months of central scotoma in her right eye, without pro- dromic symptoms. There was no history of traumatic, systematic illnesses, or a family history of eye ... See full document
6
Atypical vitelliform macular dystrophy misdiagnosed as chronic central serous chorioretinopathy: case reports
... extensive serous retinal detachment in the posterior pole of the retina (Figure ...the central area and hyperauto- fluorescence at the border of the serous retinal detach- ment (Figure ...with ... See full document
8
Photodynamic therapy versus anti-vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: A meta-analysis
... functional outcomes of PDT and intravit- real injection of anti-VEGF agents for treating PCV [7, ...in outcomes have been ...functional outcomes when treating ... See full document
9
Related subjects